Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P36871
UPID:
PGM1_HUMAN
Alternative names:
Glucose phosphomutase 1
Alternative UPACC:
P36871; B2R5N9; B4DPV0; Q16105; Q16106; Q5BKZ9; Q6NW22; Q86U74; Q96J40; Q9NTY4
Background:
Phosphoglucomutase-1 (PGM1), also known as Glucose phosphomutase 1, plays a pivotal role in glucose metabolism by facilitating both the synthesis and breakdown of glucose. This enzyme's versatility underscores its importance in maintaining glucose homeostasis, a critical aspect of cellular energy management.
Therapeutic significance:
PGM1's link to Congenital disorder of glycosylation 1T, a condition marked by a spectrum of clinical features including developmental and immunological deficits, highlights its therapeutic potential. Targeting PGM1-related pathways could offer novel interventions for managing this disorder, emphasizing the enzyme's significance in medical research.